De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ViewRay Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van ViewRay is gedaald met een gemiddeld jaarlijks percentage van -6.6%, terwijl de winst van de Medical Equipment -industrie jaarlijks groeide met 11.8%. De inkomsten zijn groeide met een gemiddeld percentage van 3% per jaar.

Belangrijke informatie

-6.6%

Groei van de winst

13.7%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie	8.9%
Inkomstengroei	3.0%
Rendement op eigen vermogen	-199.8%
Nettomarge	-104.3%
Laatste winstupdate	31 Mar 2023

Recente prestatie-updates uit het verleden

Recent updates

Opbrengsten en kosten

Hoe ViewRay geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

OTCPK:VRAY.Q Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Mar 23	106	-110	83	33
31 Dec 22	102	-107	83	32
30 Sep 22	88	-107	81	33
30 Jun 22	81	-106	77	34
31 Mar 22	73	-109	73	33
31 Dec 21	70	-110	72	32
30 Sep 21	68	-109	70	30
30 Jun 21	59	-112	72	27
31 Mar 21	58	-107	74	25
31 Dec 20	57	-108	77	25
30 Sep 20	55	-117	80	24
30 Jun 20	66	-110	88	25
31 Mar 20	82	-114	93	25
31 Dec 19	88	-120	92	24
30 Sep 19	92	-102	88	21
30 Jun 19	89	-114	81	20
31 Mar 19	75	-105	72	18
31 Dec 18	81	-79	65	17
30 Sep 18	80	-87	59	17
30 Jun 18	75	-65	49	17
31 Mar 18	59	-52	45	16
31 Dec 17	34	-72	40	15
30 Sep 17	30	-59	34	12
30 Jun 17	18	-61	32	11
31 Mar 17	18	-65	30	11
31 Dec 16	22	-51	29	11
30 Sep 16	11	-54	30	12
30 Jun 16	16	-50	28	12
31 Mar 16	16	-50	29	12
31 Dec 15	10	-45	27	10
30 Sep 15	6	-41	26	9
30 Jun 15	4	-38	25	9
31 Mar 15	5	-34	20	9
31 Dec 14	6	-34	19	9
30 Sep 14	8	-32	16	10
31 Dec 13	3	-28	13	9
31 Dec 12	2	-25	10	8

Kwaliteitswinsten: VRAY.Q is momenteel verliesgevend.

Groeiende winstmarge: VRAY.Q is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: VRAY.Q is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 6.6% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van VRAY.Q over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: VRAY.Q is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Medical Equipment industrie ( 7.9% ).

Rendement op eigen vermogen

Hoge ROE: VRAY.Q heeft een negatief Return on Equity ( -199.82% ), omdat het momenteel verliesgevend is.

ViewRay Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First quarter 2023 earnings: Revenues and EPS in line with analyst expectations

ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023

ViewRay, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Recent updates

Motion For Case Conversion Approved for ViewRay, Inc.

Nasdaq To Delist the Common Stock of ViewRay

ViewRay, Inc.(OTCPK:VRAY.Q) dropped from NASDAQ Composite Index

ViewRay Announces Commencement of Nasdaq Delisting Proceedings

ViewRay, Inc. Announces the Resignation of Sai Nanduri as Observer to the Board

Motion for Joint Administration Filed by ViewRay, Inc.

Viewray, Inc. Announces Resignation of Susan Schnabel from Board of Directors

ViewRay Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

First quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Consensus revenue estimates decrease by 16%

ViewRay, Inc. to Report Q1, 2023 Results on May 10, 2023

Market Cool On ViewRay, Inc.'s (NASDAQ:VRAY) Revenues Pushing Shares 63% Lower

Consensus revenue estimates decrease by 12%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations

ViewRay, Inc. to Report Q4, 2022 Results on Feb 27, 2023

ViewRay, Inc. Appoints Sai Nanduri as an Observer of the Board of Directors

ViewRay, Inc. Announces Findings from the Phase III Randomized Controlled Mirage Trial

ViewRay, Inc. Announces CFO Changes

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$117k worth of stock

ViewRay, Inc. Provides Revenue Guidance for the Full Year 2022

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc Announces the Final Primary Endpoint Results from the Phase III Randomized Single-Center MIRAGE Trial

ViewRay, Inc. Announces Primary Endpoint Outcome from First Prospective, Multi-Institutional Study to Deliver Ablative Doses of Radiation to Pancreatic Cancer Patients

ViewRay, Inc. Launches Phase III Pancreatic Cancer Study to Demonstrate Superior Overall Survival for Patients Receiving MRI-guided Ablative Radiation Therapy

ViewRay, Inc. to Report Q3, 2022 Results on Nov 01, 2022

ViewRay MRI-guided radiation therapy selected by SUNY upstate cancer center

ViewRay Announces China NMPA Approval of its MRIdian(R) MRI-Guided Radiation Therapy for Cancer Patients

ViewRay's MRI-guided radiation therapy gets approval in China

ViewRay MRI-guided radiation therapy selected by VA Houston Healthcare System

ViewRay, Inc. Selects Denver for Headquarters

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Viewray, Inc. Updates Earnings Guidance for the Year 2022

ViewRay, Inc. to Report Q2, 2022 Results on Aug 02, 2022

ViewRay: Insider Buying In This $3 Stock

Consensus estimates of losses per share improve by 11%

President recently bought US$400k worth of stock

Price target decreased to US$7.43

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ViewRay, Inc. Reiterates Earnings Guidance for the Year 2022

ViewRay, Inc., Annual General Meeting, Jun 10, 2022

ViewRay, Inc. to Report Q1, 2022 Results on May 05, 2022

Health Check: How Prudently Does ViewRay (NASDAQ:VRAY) Use Debt?

Insider recently bought US$96k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Viewray, Inc. Provides Revenue Guidance for the Year 2022

ViewRay Announces Interim Findings from MIRAGE Phase III Randomized Trial Signal Superiority of MRIdian® MRI-guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

ViewRay, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Chief Financial Officer recently bought US$100k worth of stock

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 3Q 2020)

Chief Financial Officer recently bought US$213k worth of stock

Price target increased to US$8.03

Is ViewRay (NASDAQ:VRAY) Using Debt Sensibly?

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 2Q 2020)

ViewRay, Inc.(NasdaqGM:VRAY) dropped from Russell Microcap Value Index

ViewRay, Inc. Not to Provide Financial Guidance

ViewRay, Inc. 2021 Q1 - Results - Earnings Call Presentation

Price target increased to US$6.32

Chief Operating Officer has left the company

ViewRay, Inc. Announces the Resignation of Shahriar Matin as Chief Operating Officer, Effective from March 31, 2021

Full year 2020 earnings released: US$0.73 loss per share (vs US$1.18 loss in FY 2019)

Revenue beats expectations

Read This Before Selling ViewRay, Inc. (NASDAQ:VRAY) Shares

ViewRay, Inc. to Report Q4, 2020 Results on Mar 04, 2021

ViewRay, Inc. Announces Retirement of D. Keith Grossman from Board of Directors

Viewray, Inc. Appoints Phil Spencer to Its Board of Directors

Edogawa Hospital in Tokyo Installs Japan's First ViewRay MRIdian Linac

The Henry Ford Cancer Institute Installs Its Second Viewray Mridian® Linac

How Many ViewRay, Inc. (NASDAQ:VRAY) Shares Do Institutions Own?